Current role
Biotechnology · Healthcare
CEO, Board Member
2007-01-01–present
Todd C. Davis
Board Member
Ligand Pharmaceuticals Inc (LGND)Equibles does not estimate personal net worth.
Get an email with a short summary when Ligand Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get LGND alertsAbout Todd C. Davis
Todd C. Davis is recorded as Board Member at Ligand Pharmaceuticals Inc (LGND) since January 1, 2007 and CEO at Ligand Pharmaceuticals Inc (LGND). The newest filing on record that lists Todd C. Davis as CEO and Board Member at Ligand Pharmaceuticals Inc (LGND) is dated April 21, 2026. Ligand Pharmaceuticals Inc reported in an 8-K filed June 9, 2026 that Todd C. Davis was appointed director of the Company, effective June 5, 2026. Ligand Pharmaceuticals Inc reported in an 8-K filed June 17, 2024 that Todd C. Davis was appointed director. Ligand Pharmaceuticals Inc reported in an 8-K filed December 5, 2022 that Todd C. Davis was appointed Chief Executive Officer, effective December 5, 2022. The proxy statement of Ligand Pharmaceuticals Inc reports total compensation of $11,472,095 for Todd C. Davis in fiscal 2025, including a base salary of $724,500. Disclosed compensation is on record for 4 fiscal years. Ligand Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ligand Pharmaceuticals Inc includes Tavo Espinoza (CFO), Jason Haas (Board Member), Jason M. Aryeh (Board Member) and 7 others.
“Todd C. Davis | 17,224,372 | 309,387 | 1,257,231”
“each nominee was elected to serve as a director of the Company.”
Affiliation history
-
Current
2007-01-01–present
Last confirmed April 21, 2026
-
Current
Start not stated–present
Last confirmed April 21, 2026
Company network
Leadership on record at Ligand Pharmaceuticals Inc
- Tavo Espinoza CFO
- Jason Haas Board Member
- Jason M. Aryeh Board Member
- Jennifer Cochran, Ph.D. Board Member
- John L. LaMattina Board Member
- John L. LaMattina, Ph.D. Board Member
- John W. Kozarich Board Member
- John W. Kozarich, Ph.D. Board Member
- Martine Zimmermann Board Member
- Martine Zimmermann, Pharm.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ligand Pharmaceuticals Inc (LGND) | Chief Executive Officer | $724,500 | $11,472,095 |
| 2024 | Ligand Pharmaceuticals Inc (LGND) | Chief Executive Officer | $695,834 | $12,914,980 |
| 2023 | Ligand Pharmaceuticals Inc (LGND) | Chief Executive Officer | $650,007 | $6,216,518 |
| 2022 | Ligand Pharmaceuticals Inc (LGND) | Chief Executive Officer | $49,243 | $5,195,169 |